A prospective evaluation of insulin dosing recommendations in patients with Type 1 diabetes at near normal glucose control: Basal dosing

Journal of Diabetes Science and Technology

Volumn 1, Issue 1, 2007, Pages 36-41

  King, Allen B ^a   Armstrong, Dana U ^a  

^a Diabetes Care Center   (United States)

Author keywords

Basal; Diabetes; Glucose; Insulin; Pump

Indexed keywords

EID: 67649155391     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680700100106     Document Type: Article

References (12)

1. Bode BW. Insulin Pump Therapy. In, Therapy for Diabetes Mellitus and Related Disorder, fourth edition. Lebovitz H, Ed. Alexandria, VA, American Diabetes Association, 2004, p. 224-231.
2. Davidson PC, Hebblewhite HR, Bode BW, Steed RD, Welch NS, Greenlee MC, Richardson PL, Johnson J: Statistically based CSII parameters: correction factor, CF (1700 rule), carbohydrate-to-insulin ratio, CIR (2.8 rule), and basal-to-total ratio. Diabetes Technol Ther 2003;3:237.
3. Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV: Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with Type 1 diabetes. Diabetes Care 2001;24:1858-1862.
4. Gross TM, Mastrototaro JJ: Effcacy and reliability of the continuous glucose monitoring system. Diabetes Technol Ther 2000;2(supplement 1):S19-26.
5. Ludvigsson J, Hanas R: Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with Type 1 diabetes: a controlled crossover study. Pediatrics 2003;111:933-938.
6. Kaufman FR, Gibson LC, Halvorson M, Carpenter S, Fisher LK, Pitukcheewanont P: A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric Type 1 diabetic subjects. Diabetes Care 2001;24:2030-2034.
7. Wolpert H. Smart Pumping for people with diabetes. Alexandra, VA American Diabetes Association, 2002.
8. King AB, Armstrong DU: Daily Glucose Trend Analyses and Treatment Adjustments Using the Continuous Glucose Monitoring System (CGMS, Medtronic MiniMed): "Tweaking". Diabetes Technol & Ther 2004;6:297.
9. Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hus P, Santiago OM, Kolacynski JW: Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in Type 1 diabetic patients previously treated with CSII. Diabetes Care 2005;28:533-538.
10. Carroll MF, Schade DS: The dawn phenomenon revisited: implications for diabetes therapy. Endocr Pract 2005;11:55-64.
11. King AB, Armstrong DU: A comparison of basal insulin delivery: continuous subcutaneous insulin infusion versus glargine. Diabetes Care 2003;26:1322.
12. Perriello G, De Feo P, Torlone E, Fanelli C, Santeusanio F, Brunetti P, Bolli GB: The dawn phenomenon in Type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity. Diabetologia 1991;34:21-28.